Martin Ingman will be responsible for building Moberg Derma’s international network of distributors as well as the company’s sales organisation for the Nordic markets. Martin brings 15 years of experience within sales and marketing. His latest position was as Marketing Director at Carema and previously he held leading commercial positions at Q-Med and Astra.
Moberg Derma is developing several dermatological pharmaceuticals based on the company’s patented Kaprolac® principle. The company prepares the launch of its first two products, a solution and a shampoo against seborrheic dermatitis and dandruff, during the second half of 2009. Recently positive results were reported from a clinical phase III study for K101 against nail fungus. Further, a clinical phase II study for K201 against atopic dermatitis will be initiated in January 2009.
